Insulet reports ‘robust’ quarter
By HME News Staff
Updated 9:18 AM CDT, Thu August 7, 2025
ACTON, Mass. - Insulet reported revenue of $649.1 million for the second quarter of 2025, up 32.9% compared to the same period last year.
Total Omnipod revenue was $639 million, up 33%. Of that, U.S. Omnipod revenue was $453.2 million, up 28.7%, and international Omnipod revenue was $185.8 million, up 45%. Adjusted EBITDA was $157.5 million.
“We delivered robust second quarter results, reflecting our team’s strong performance and the compelling impact and appeal of Omnipod 5 for people living with diabetes,” said Ashley McEvoy, president and CEO. “Engaging with our partners, physicians, investors and Podders this quarter has demonstrated our opportunity to revolutionize diabetes management and the value of our unique position at the nexus of consumer health, medtech and health tech. As we scale the company, I’m confident in our ability to grow and create value for all our stakeholders in the future.”
McEvoy was recently named to the role, succeeding Jim Hollingshead.
Recent strategic highlights:
-
Announced Omnipod 5 App for iPhone compatible with Dexcom’s G7 Continuous Glucose Monitor (CGM) sensor fully available in the U.S.
-
Integrated Omnipod 5 with Dexcom’s G7 CGM sensor in Germany and Abbott's FreeStyle Libre 2 Plus CGM sensor in Australia.
-
Collaborated with Marvel to launch comic book hero, Dyasonic, who lives with Type 1 diabetes.
Comments